CpG island shore methylation regulates caveolin-1 expression in breast cancer

Caveolin-1 (Cav1) is an integral membrane, scaffolding protein found in plasma membrane invaginations (caveolae). Cav1 regulates multiple cancer-associated processes. In breast cancer, a tumor suppressive role for Cav1 has been suggested; however, Cav1 is frequently overexpressed in aggressive breast cancer subtypes, suggesting an oncogenic function in advanced-stage disease. To further delineate Cav1 function in breast cancer progression, we evaluated its expression levels among a panel of cell lines representing a spectrum of breast cancer phenotypes. In basal-like (the most aggressive BC subtype) breast cancer cells, Cav1 was consistently upregulated, and positively correlated with increased cell proliferation, anchorage-independent growth, and migration and invasion. To identify mechanisms of Cav1 gene regulation, we compared DNA methylation levels within promoter ‘CpG islands’ (CGIs) with ‘CGI shores’, recently described regions that flank CGIs with less CG-density. Integration of genome-wide DNA methylation profiles (‘methylomes’) with Cav1 expression in 30 breast cancer cell lines showed that differential methylation of CGI shores, but not CGIs, significantly regulated Cav1 expression. In breast cancer cell lines having low Cav1 expression (despite promoter CGI hypomethylation), we found that treatment with a DNA methyltransferase inhibitor induced Cav1 expression via CGI shore demethylation. In addition, further methylome assessments revealed that breast cancer aggressiveness associated with Cav1 CGI shore methylation levels, with shore hypermethylation in minimally aggressive, luminal breast cancer cells and shore hypomethylation in highly aggressive, basal-like cells. Cav1 CGI shore methylation was also observed in human breast tumors, and overall survival rates of breast cancer patients lacking estrogen receptor α (ERα) negatively correlated with Cav1 expression. Based on this first study of Cav1 (a potential oncogene) CGI shore methylation, we suggest this phenomenon may represent a new prognostic marker for ERα-negative, basal-like breast cancer.

[1]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[2]  Steven J. M. Jones,et al.  Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. , 2008, Cancer research.

[3]  G. Fiucci,et al.  Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells , 2002, Oncogene.

[4]  M. Lisanti,et al.  Interaction of a Receptor Tyrosine Kinase, EGF-R, with Caveolins , 1997, The Journal of Biological Chemistry.

[5]  J. Engelman,et al.  Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3) , 1998, FEBS letters.

[6]  M. Dowsett,et al.  The role of caveolin-1 in human breast cancer , 2011, Breast Cancer Research and Treatment.

[7]  Ivo G Gut,et al.  DNA methylation analysis by pyrosequencing , 2007, Nature Protocols.

[8]  E. Levin,et al.  ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. , 2002, Molecular endocrinology.

[9]  B. van der Burg,et al.  Estrogen Receptor (cid:1) -mediated Silencing of Caveolin Gene Expression in Neuronal Cells* , 2002 .

[10]  M. Lisanti,et al.  Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. , 1996, The Journal of biological chemistry.

[11]  J. Pink,et al.  An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. , 1995, Cancer research.

[12]  M Dietel,et al.  Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. , 2001, The American journal of pathology.

[13]  P. Insel,et al.  Caveolae as organizers of pharmacologically relevant signal transduction molecules. , 2008, Annual review of pharmacology and toxicology.

[14]  Peng Huang,et al.  Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. , 2011, Cancer research.

[15]  J. Engelman,et al.  Sequence and detailed organization of the human caveolin‐1 and ‐2 genes located near the D7S522 locus (7q31.1) , 1999, FEBS letters.

[16]  H. Werner,et al.  Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways. , 2006, Experimental cell research.

[17]  C. Maier,et al.  Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. , 2008, Cancer genetics and cytogenetics.

[18]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[19]  P. Insel,et al.  The evolving role of lipid rafts and caveolae in G protein‐coupled receptor signaling: implications for molecular pharmacology , 2004, British journal of pharmacology.

[20]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[21]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[22]  S. Woodman,et al.  Caveolae: From Cell Biology to Animal Physiology , 2002, Pharmacological Reviews.

[23]  David Serre,et al.  MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome , 2009, Nucleic acids research.

[24]  C. Allis,et al.  DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA , 2007, Nature.

[25]  Paul J Johnson,et al.  Good, the bad, and the ugly. , 2000, Occupational health & safety.

[26]  K. Mimori,et al.  Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer , 2004, British Journal of Cancer.

[27]  I. Ng,et al.  Caveolin‐1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis , 2012, The Journal of pathology.

[28]  Shou‐Tung Chen,et al.  Promoter CpG methylation of caveolin-1 in sporadic colorectal cancer. , 2004, Anticancer research.

[29]  D. Matei,et al.  A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer , 2010, Cancer.

[30]  Gavin D. Meredith,et al.  High Resolution Detection and Analysis of CpG Dinucleotides Methylation Using MBD-Seq Technology , 2011, PloS one.

[31]  H. Werner,et al.  Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling , 2005, Oncogene.

[32]  Richard G. W. Anderson,et al.  Multiple Functions of Caveolin-1* , 2002, The Journal of Biological Chemistry.

[33]  Charles C. Wykoff,et al.  Recombinant Expression of Caveolin-1 in Oncogenically Transformed Cells Abrogates Anchorage-independent Growth* , 1997, The Journal of Biological Chemistry.

[34]  S. Wiseman,et al.  Caveolin-1 in tumor progression: the good, the bad and the ugly , 2008, Cancer and Metastasis Reviews.

[35]  S. Merajver,et al.  Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer , 2006, Breast Cancer Research and Treatment.

[36]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[37]  Sandya Liyanarachchi,et al.  Molecular and Cellular Pathobiology Epigenetic Silencing Mediated through Activated PI 3 K / AKT Signaling in Breast Cancer , 2011 .

[38]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[39]  Michael Q. Zhang,et al.  Large-scale structure of genomic methylation patterns. , 2005, Genome research.

[40]  M. Lisanti,et al.  Caveolin-1 in oncogenic transformation, cancer, and metastasis. , 2005, American journal of physiology. Cell physiology.

[41]  Peter A. Jones,et al.  Rethinking how DNA methylation patterns are maintained , 2009, Nature Reviews Genetics.

[42]  George Reid,et al.  Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines , 1999, Oncogene.

[43]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[44]  M. Shatz,et al.  Caveolin-1: A tumor-promoting role in human cancer , 2008, International journal of radiation biology.

[45]  Chiang-Ching Huang,et al.  TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. , 2008, Cancer research.

[46]  T. Mak,et al.  The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk , 2011, Oncogene.

[47]  Peter A. Jones,et al.  DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. , 2011, Human molecular genetics.

[48]  J. Couet,et al.  Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells , 2003, Anti-cancer drugs.

[49]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[50]  M. Dowsett,et al.  Non-existence of caveolin-1 gene mutations in human breast cancer , 2011, Breast Cancer Research and Treatment.

[51]  J. Minna,et al.  Different Roles for Caveolin-1 in the Development of Non-Small Cell Lung Cancer versus Small Cell Lung Cancer , 2004, Cancer Research.

[52]  R. Nicholson,et al.  Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance , 2010, Breast Cancer Research and Treatment.

[53]  Lang Li,et al.  Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. , 2006, Cancer research.

[54]  Jan-Gowth Chang,et al.  Mutational, epigenetic and expressional analyses of caveolin-1 gene in cervical cancers. , 2003, International journal of oncology.

[55]  Martin J Aryee,et al.  Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts , 2009, Nature Genetics.

[56]  A. Bird,et al.  CpG islands and the regulation of transcription. , 2011, Genes & development.

[57]  S. Kim,et al.  Caveolin‐1 is down‐regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast , 2005, Histopathology.

[58]  Robin L. Jones,et al.  Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis , 2007, Clinical Cancer Research.

[59]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[60]  I. Ellis,et al.  Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype , 2008, British Journal of Cancer.